How much progress are we making toward solving this neurological disorder? Scientists from Charles River Laboratories and Teva Pharmaceuticals discuss the state of the science. Listen and learn.  

Over two million people worldwide suffer from multiple sclerosis, one of the most common in a collection of disorders known as demyelinating diseases. Destruction of the protective sheath is the hallmark symptom, but there are many other unpleasant consequences of MS as well as many different disease courses. Treating it, therefore, can be tricky. There are a dozen or so drugs that modify the course of the disease and many, many other drugs that address the depression, bladder and bowel problems, fatigue, itching and pain caused by MS. But there is no cure for MS and even with treatment, MS inevitably progresses. At the Society for Neuroscience meeting earlier this month, Antti Nurmi, the Director of Science for Charles River Laboratories’ Discovery Research Services site in Kuopio, Finland, spoke with Ian Reynolds, VP and CNS Discovery Lead for Teva Pharmaceuticals about the current state of MS research, the up and coming use of stem cells to treat MS and the development of a unique consortium that is seeking better ways of modeling MS disease. If you are interested in learning more about MS research, check out these other Eureka blogs on the MS Consortium and the cuprizone model.